WSJ Article - Merck Pursues Biotech Seagen Amaz
Post# of 148175
(Total Views: 633)
Posted On: 06/19/2022 9:54:12 AM
WSJ Article - Merck Pursues Biotech Seagen
Amazing the parallels between this company and us. Both based in WA state, both between CEOs, both have a cancer drug being tried in combination with existing therapy, and i think their drug is a MAB also.
Of course, the difference is that Seagen has an approval, and generates revenue. Incredibly, it has a market cap of $30 Billion on just $1.6 Billion in revenue. That's a 19X revenue multiple - shows how much money we all make if we could just start generating revenue.
Article also mentions that M&A hit an all time high last year, and down 50% this year - but still good. In other words, we're still in the golden window of being bought - but nothing lasts forever.
It's time for us to get out on the field. There's one helluva game taking place out there - and it's just waiting for us. Companies are dying to buy a quality drug like ours - and make us rich in the process. But we've got to make some progress, get this regulatory hold lifted, and finally leave the locker room and get out on the field.
Amazing the parallels between this company and us. Both based in WA state, both between CEOs, both have a cancer drug being tried in combination with existing therapy, and i think their drug is a MAB also.
Of course, the difference is that Seagen has an approval, and generates revenue. Incredibly, it has a market cap of $30 Billion on just $1.6 Billion in revenue. That's a 19X revenue multiple - shows how much money we all make if we could just start generating revenue.
Article also mentions that M&A hit an all time high last year, and down 50% this year - but still good. In other words, we're still in the golden window of being bought - but nothing lasts forever.
It's time for us to get out on the field. There's one helluva game taking place out there - and it's just waiting for us. Companies are dying to buy a quality drug like ours - and make us rich in the process. But we've got to make some progress, get this regulatory hold lifted, and finally leave the locker room and get out on the field.
(8)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼